The postprandial situation as a pro-inflammatory condition

Clinica e Investigacion en Arteriosclerosis

Volumn 26, Issue 4, 2014, Pages 184-192

  de Vries, Marijke A ^a   Klop, Boudewijn ^a   Eskes, Silvia A ^a   van der Loos, Theo L J M ^a   Klessens Godfroy, Françoise J M ^a   Wiebolt, Janneke ^a   Janssen, Hans W ^a   Westerman, Elsbeth M ^a   Castro Cabezas, Manuel ^a  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Apolipoprotein B48; Atherosclerosis; Chylomicron; Triglyceride

Indexed keywords

ANTIDIABETIC AGENT; ATORVASTATIN; CHYLOMICRON; FENOFIBRATE; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DOWN REGULATION; DRUG MECHANISM; FAMILIAL HYPERLIPEMIA; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LEUKOCYTE ACTIVATION; LIFESTYLE MODIFICATION; LIPOLYSIS; OXIDATIVE STRESS; PATHOGENESIS; POSTPRANDIAL STATE; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION;

EID: 84904797599     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2014.02.007     Document Type: Short Survey

References (99)

1. Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., Barnes E.H., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
2. Arsenault B.J., Rana J.S., Stroes E.S.G., Després J.-P., Shah P.K., Kastelein J.J.P., et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009, 55:35-41.
3. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
4. Sniderman A.D., Williams K., Contois J.H., Monroe H.M., McQueen M.J., de Graaf J., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
5. Albers J.J., Slee A., O'Brien K.D., Robinson J.G., Kashyap M.L., Kwiterovich P.O., et al. Relationship of apolipoproteins A-1 and B, and lipoprotein (a) to cardiovascular outcomes in the AIM-HIGH trial. J Am Coll Cardiol 2013, 62:1575-1579.
6. Jackson K.G., Poppitt S.D., Minihane A.M. Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants. Atherosclerosis 2012, 220:22-33.
7. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:2045-2051.
8. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
9. Klop B., Proctor S.D., Mamo J.C., Botham K.M., Castro Cabezas M. Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases. Int J Vasc Med 2012, 2012:947417.
10. Klop B., Castro Cabezas M. Chylomicrons: a key biomarker and risk factor for cardiovascular disease and for the understanding of obesity. Curr Cardiovasc Risk Rep 2011, 6:27-34.
11. Alipour A., Elte J.W.F., van Zaanen H.C.T., Rietveld A.P., Castro Cabezas M. Novel aspects of postprandial lipemia in relation to atherosclerosis. Atheroscler Suppl 2008, 9:39-44.
12. Abumrad N.A., Davidson N.O. Role of the gut in lipid homeostasis. Physiol Rev 2012, 92:1061-1085.
13. Xiao C., Lewis G.F. Regulation of chylomicron production in humans. Biochim Biophys Acta 2012, 1821:736-746.
14. Haberbosch W., Poli A., Augustin J. Characterization of human chylomicrons. Biochim Biophys Acta 1982, 713:398-409.
15. Wang T.Y., Liu M., Portincasa P., Wang D.Q.H. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur J Clin Invest 2013, 43:1203-1223.
16. Buttet M., Traynard V., Tran T.T.T., Besnard P., Poirier H., Niot I. From fatty-acid sensing to chylomicron synthesis: role of intestinal lipid-binding proteins. Biochimie 2013, 966:37-47.
17. Iqbal J., Hussain M.M. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009, 296:E1183-E1194.
18. Phillips C., Mullan K., Owens D., Tomkin G.H. Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis 2006, 187:57-64.
19. Siddiqi S., Saleem U., Abumrad N.A., Davidson N.O., Storch J., Siddiqi S.A., et al. A novel multiprotein complex is required to generate the prechylomicron transport vesicle from intestinal ER. J Lipid Res 2010, 51:1918-1928.
20. Mansbach C.M., Gorelick F. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am J Physiol Gastrointest Liver Physiol 2007, 293:G645-G650.
21. Mansbach C.M., Siddiqi S.A. The biogenesis of chylomicrons. Annu Rev Physiol 2010, 72:315-333.
22. Brunzell J.D., Hazzard W.R., Porte D., Bierman E.L. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973, 52:1578-1585.
23. Van Beek A.P., van Barlingen H.H., de Ruijter-Heijstek F.C., Jansen H., Erkelens D.W., Dallinga-Thie G.M., et al. Preferential clearance of apoB-48-containing lipoproteins after heparin-induced lipolysis is modulated by lipoprotein lipase activity. J Lipid Res 1998, 39:322-332.
24. Redgrave T.G. Formation and metabolism of chylomicrons. Int Rev Physiol 1983, 28:103-130.
25. Dallinga-Thie G.M., Franssen R., Mooij H.L., Visser M.E., Hassing H.C., Peelman F., et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010, 211:1-8.
26. Williams K.J. Molecular processes that handle - and mishandle - dietary lipids. J Clin Invest 2008, 118:3247-3259.
27. Nguyen P., Leray V., Diez M., Serisier S., Le Bloc'h J., Siliart B., et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 2008, 92:272-283.
28. Koutsari C., Mundi M.S., Ali A.H., Patterson B.W., Jensen M.D. Systemic free fatty acid disposal into very low-density lipoprotein triglycerides. Diabetes 2013, 62:2386-2395.
29. Castro Cabezas M., Halkes C.J., Meijssen S., Van Oostrom A.J., Erkelens D.W. Diurnal triglyceride profiles: a novel approach to study triglyceride changes. Atherosclerosis 2001, 155:219-228.
30. Van Wijk J.P., Castro Cabezas M., Halkes C.J., Erkelens D.W. Effects of different nutrient intakes on daytime triacylglycerolemia in healthy, normolipemic, free-living men. Am J Clin Nutr 2001, 74:171-178.
31. Alipour A., Valdivielso P., Elte J.W.F., Janssen H.W., Rioja J., van der Meulen N., et al. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur J Clin Invest 2012, 42:702-708.
32. Brunzell J.D., Zambon A., Deeb S.S. The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. Biochim Biophys Acta 2012, 1821:365-372.
33. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
34. Varbo A., Benn M., Tybjærg-Hansen A., Jørgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436.
35. Norata G.D., Raselli S., Grigore L., Garlaschelli K., Vianello D., Bertocco S., et al. Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis 2009, 206:556-562.
36. Brunzell J.D., Albers J.J., Chait A., Grundy S.M., Groszek E., McDonald G.B. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983, 24:147-155.
37. Castro Cabezas M., Halkes C.J., Erkelens D.W. Obesity and free fatty acids: double trouble. Nutr Metab Cardiovasc Dis 2001, 11:134-142.
38. Lopez-Miranda J., Williams C., Lairon D. Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr 2007, 98:458-473.
39. Parra E.S., Urban A., Panzoldo N.B., Nakamura R.T., Oliveira R., de Faria E.C. A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic women. Lipids Heal Dis 2011, 10:87.
40. Vansant G., Mertens A., Muls E. Determinants of postprandial lipemia in obese women. Int J Obes Relat Metab Disord 1999, 23(Suppl. 1):14-21.
41. Van Oostrom A.J.H.H., Alipour A., Plokker T.W.M., Sniderman A.D., Castro Cabezas M. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 2007, 190:167-173.
42. Masana L., Ribalta J., Salazar J., Fernández-Ballart J., Joven J., Cabezas M.C. The apolipoprotein AV gene and diurnal triglyceridaemia in normolipidaemic subjects. Clin Chem Lab Med 2003, 41:517-521.
43. Van Oostrom A.J., Castro Cabezas M., Ribalta J., Masana L., Twickler T.B., Remijnse T.A., et al. Diurnal triglyceride profiles in healthy normolipidemic male subjects are associated to insulin sensitivity, body composition and diet. Eur J Clin Invest 2000, 30:964-971.
44. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199-204.
45. Friedman G.D., Klatsky A.L., Siegelaub A.B. The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974, 290:1275-1278.
46. Meijssen S., van Dijk H., Verseyden C., Erkelens D.W., Castro Cabezas M. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arter Thromb Vasc Biol 2002, 22:811-816.
47. Muscari A., Massarelli G., Bastagli L., Poggiopollini G., Tomassetti V., Drago G., et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Hear J 2000, 21:1081-1090.
48. Schmidt M.I., Duncan B.B., Sharrett A.R., Lindberg G., Savage P.J., Offenbacher S., et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649-1652.
49. Verseyden C., Meijssen S., van Dijk H., Jansen H., Castro Cabezas M. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J Lipid Res 2003, 44:2100-2108.
50. Varbo A., Benn M., Tybjærg-Hansen A., Nordestgaard B.G. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013, 128:1298-1309.
51. Okada K., Furusyo N., Murata M., Sawayama Y., Kainuma M., Hayashi J. A hypertriglyceridemic state increases high sensitivity C-reactive protein of Japanese men with normal glucose tolerance. Endocrine 2012, 41:96-102.
52. Eriksson E.E., Xie X., Werr J., Thoren P., Lindbom L. Direct viewing of atherosclerosis in vivo: plaque invasion by leukocytes is initiated by the endothelial selectins. FASEB J 2001, 15:1149-1157.
53. Huo Y., Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand 2001, 173:35-43.
54. Murohara T., Buerke M., Lefer A.M. Polymorphonuclear leukocyte-induced vasocontraction and endothelial dysfunction. Role of selectins. Arter Thromb 1994, 14:1509-1519.
55. Alipour A., Van Oostrom A.J.H.H., Izraeljan A., Verseyden C., Collins J.M., Frayn K.N., et al. Leukocyte activation by triglyceride-rich lipoproteins. Arter Thromb Vasc Biol 2008, 28:792-797.
56. Bentley C., Hathaway N., Widdows J., Bejta F., De Pascale C., Avella M., et al. Influence of chylomicron remnants on human monocyte activation in vitro. Nutr Metab Cardiovasc Dis 2011, 21:871-878.
57. Wanten G., van Emst-De Vries S., Naber T., Willems P. Nutritional lipid emulsions modulate cellular signaling and activation of human neutrophils. J Lipid Res 2001, 42:428-436.
58. Van Oostrom A.J.H.H., Rabelink T.J., Verseyden C., Sijmonsma T.P., Plokker H.W.M., De Jaegere P.P.T., et al. Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis 2004, 177:175-182.
59. Den Hartigh L.J., Altman R., Norman J.E., Rutledge J.C. Postprandial VLDL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFκB. Am J Physiol Hear Circ Physiol 2013, 306:H109-H120.
60. Kuhel D.G., Konaniah E.S., Basford J.E., McVey C., Goodin C.T., Chatterjee T.K., et al. Apolipoprotein E2 accentuates postprandial inflammation and diet-induced obesity to promote hyperinsulinemia in mice. Diabetes 2013, 62:382-391.
61. Nguyen A., Tao H., Metrione M., Hajri T. Very low density lipoprotein receptor expression is a determinant factor in adipose tissue inflammation and adipocyte-macrophage interaction. J Biol Chem 2013, [Epub ahead of print].
62. Gower R.M., Wu H., Foster G.A., Devaraj S., Jialal I., Ballantyne C.M., et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011, 31:160-166.
63. Koo C., Wernette-Hammond M.E., Garcia Z., Malloy M.J., Uauy R., East C., et al. Uptake of cholesterol-rich remnant lipoproteins by human monocyte-derived macrophages is mediated by low density lipoprotein receptors. J Clin Invest 1988, 81:1332-1340.
64. Skrede B., Blomhoff R., Maelandsmo G.M., Ose L., Myklebost O., Norum K.R. Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo. Eur J Clin Invest 1992, 22:229-234.
65. Tertov V.V., Kalenich O.S., Orekhov A.N. Lipid-laden white blood cells in the circulation of patients with coronary heart disease. Exp Mol Pathol 1992, 57:22-28.
66. Bermudez B., Lopez S., Varela L.M., Ortega A., Pacheco Y.M., Moreda W., et al. Triglyceride-rich lipoprotein regulates APOB48 receptor gene expression in human THP-1 monocytes and macrophages. J Nutr 2012, 142:227-232.
67. Van Oostrom A.J.H.H., Sijmonsma T.P., Verseyden C., Jansen E.H.J.M., de Koning E.J.P., Rabelink T.J., et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 2003, 44:576-583.
68. Adibhatla R.M., Hatcher J.F. Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep 2008, 41:560-567.
69. Natarajan R., Reddy M.A., Malik K.U., Fatima S., Khan B.V. Signaling mechanisms of nuclear factor-kappab-mediated activation of inflammatory genes by 13-hydroperoxyoctadecadienoic acid in cultured vascular smooth muscle cells. Arter Thromb Vasc Biol 2001, 21:1408-1413.
70. Mazière C., Mazière J.C. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radic Biol Med 2009, 46:127-137.
71. Robbesyn F., Salvayre R., Negre-Salvayre A. Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic Res 2004, 38:541-551.
72. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
73. Beutler B.A. TLRs and innate immunity. Blood 2009, 113:1399-1407.
74. Miller Y.I., Viriyakosol S., Binder C.J., Feramisco J.R., Kirkland T.N., Witztum J.L. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003, 278:1561-1568.
75. Rosenson R.S., Huskin A.L., Wolff D.A., Helenowski I.B., Rademaker A.W. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 2008, 198:381-388.
76. El Khoury D., Hwalla N., Frochot V., Lacorte J.-M., Chabert M., Kalopissis A.D. Postprandial metabolic and hormonal responses of obese dyslipidemic subjects with metabolic syndrome to test meals, rich in carbohydrate, fat or protein. Atherosclerosis 2010, 210:307-313.
77. Motton D.D., Keim N.L., Tenorio F.A., Horn W.F., Rutledge J.C. Postprandial monocyte activation in response to meals with high and low glycemic loads in overweight women. Am J Clin Nutr 2007, 85:60-65.
78. Van Oostrom A.J.H.H., Sijmonsma T.P., Rabelink T.J., Van Asbeck B.S., Castro Cabezas M. Postprandial leukocyte increase in healthy subjects. Metabolism 2003, 52:199-202.
79. Zambon A., Puato M., Faggin E., Grego F., Rattazzi M., Pauletto P. Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: a flag for non-HDL-C. Atherosclerosis 2013, 230:106-109.
80. Carter A.M., Prasad U.K., Grant P.J. Complement C3 and C-reactive protein in male survivors of myocardial infarction. Atherosclerosis 2009, 203:538-543.
81. Torzewski J., Torzewski M., Bowyer D.E., Fröhlich M., Koenig W., Waltenberger J., et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arter Thromb Vasc Biol 1998, 18:1386-1392.
82. Halkes C.J., van Dijk H., de Jaegere P.P., Plokker H.W., van Der Helm Y., Erkelens D.W., et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arter Thromb Vasc Biol 2001, 21:1526-1530.
83. Scantlebury T., Sniderman A.D., Cianflone K. Regulation by retinoic acid of acylation-stimulating protein and complement C3 in human adipocytes. Biochem J 2001, 356(Pt 2):445-452.
84. Cianflone K., Xia Z., Chen L.Y. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003, 1609:127-143.
85. Li Z., Wong A., Henning S.M., Zhang Y., Jones A., Zerlin A., et al. Hass avocado modulates postprandial vascular reactivity and postprandial inflammatory responses to a hamburger meal in healthy volunteers. Food Funct 2013, 4:384-391.
86. Perez-Herrera A., Delgado-Lista J., Torres-Sanchez L.A., Rangel-Zuñiga O.A., Camargo A., Moreno-Navarrete J.M., et al. The postprandial inflammatory response after ingestion of heated oils in obese persons is reduced by the presence of phenol compounds. Mol Nutr Food Res 2012, 56:510-514.
87. Sardo C.L., Kitzmiller J.P., Apseloff G., Harris R.B., Roe D.J., Stoner G.D., et al. An open-label randomized crossover trial of lyophilized black raspberries on postprandial inflammation in older overweight males: a pilot study. Am J Ther 2013, [Epub ahead of print].
88. Burton-Freeman B., Linares A., Hyson D., Kappagoda T. Strawberry modulates LDL oxidation and postprandial lipemia in response to high-fat meal in overweight hyperlipidemic men and women. J Am Coll Nutr 2010, 29:46-54.
89. Derosa G., Cicero A.F.G., Fogari E., D'Angelo A., Bonaventura A., Romano D., et al. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol 2012, 6:553-564.
90. Schirmer S.H., Werner C.M., Binder S.B.G., Faas M.E., Custodis F., Böhm M., et al. Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation. Atherosclerosis 2012, 225:166-172.
91. Burton-Freeman B., Talbot J., Park E., Krishnankutty S., Edirisinghe I. Protective activity of processed tomato products on postprandial oxidation and inflammation: a clinical trial in healthy weight men and women. Mol Nutr Food Res 2012, 56:622-631.
92. Naissides M., Mamo J.C.L., James A.P., Pal S. The effect of chronic consumption of red wine on cardiovascular disease risk factors in postmenopausal women. Atherosclerosis 2006, 185:438-445.
93. Clemente-Postigo M., Queipo-Ortuño M.I., Boto-Ordoñez M., Coin-Aragüez L., Roca-Rodriguez M.D.M., Delgado-Lista J., et al. Effect of acute and chronic red wine consumption on lipopolysaccharide concentrations. Am J Clin Nutr 2013, 97:1053-1061.
94. Strohacker K., Breslin W.L., Carpenter K.C., Davidson T.R., Agha N.H., McFarlin B.K. Moderate-intensity, premeal cycling blunts postprandial increases in monocyte cell surface CD18 and CD11a and endothelial microparticles following a high-fat meal in young adults. Appl Physiol Nutr Metab 2012, 37:530-539.
95. Brandauer J., Landers-Ramos R.Q., Jenkins N.T., Spangenburg E.E., Hagberg J.M., Prior S.J. Effects of prior acute exercise on circulating cytokine concentration responses to a high-fat meal. Physiol Rep 2013, 1:e00040.
96. Okopień B., Krysiak R., Herman Z.S. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006, 91:1770-1778.
97. Van Oostrom A.J.H.H., Plokker H.W.M., van Asbeck B.S., Rabelink T.J., van Kessel K.P.M., Jansen E.H.J.M., et al. Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis 2006, 185:331-339.
98. Van Wijk J., Coll B., Castro Cabezas M., Koning E., Camps J., Mackness B., et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol 2006, 33:1134-1137.
99. Coll B., van Wijk J.P.H., Parra S., Castro Cabezas M., Hoepelman I.M., Alonso-Villaverde C., et al. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. Eur J Pharmacol 2006, 544:104-110.